Abstract
ImmunoPET is a non-invasive imaging technology based on tracking and quantification of radiolabeled monoclonal antibodies, antibody fragments and peptides in vivo. The knowledge of distribution and expression levels of a given receptor is a key for successful receptor targeted cancer therapy. ImmunoPET performed with probes with high affinity and specificity to a given receptor aspires to be a method for obtaining comprehensive information about current in vivo status of the targeted receptor. This review describes methods for radiolabeling of peptides, monoclonal antibodies, and antibody fragments for immunoPET and highlights the recently reported pre-clinical and clinical applications of immunoPET in receptor targeted therapy.
Keywords: Imaging technology, immunoPET, monoclonal antibodies, radiolabeling, receptor targeted therapy, THIOMAB, trastuzumab, HER2, Herceptin, antibody-drug conjugates, ADC, single photon computed tomography, positron emission tomography, PET, 4-fluorobenzoic acid (FBA), 2-fluoropropionic acid (FPA), N-succinimidyl 4-fluorobenzoate, SFB, hydrazinonicotinic acid, copper-I catalyzed 1,3- dipolar cycloaddition, CuAAC, N-succinimidyl 3-iodobenzoate, SIB, 1-2 desferrioxamine, Zevalin, Epidermal Growth Factor Receptor, cetuximab, panitumumab, gefitinib, erlotinib, hEGF
Current Drug Delivery
Title: Emerging Role of ImmunoPET in Receptor Targeted Cancer Therapy
Volume: 8 Issue: 1
Author(s): Jan Marik and Jagath R. Junutula
Affiliation:
Keywords: Imaging technology, immunoPET, monoclonal antibodies, radiolabeling, receptor targeted therapy, THIOMAB, trastuzumab, HER2, Herceptin, antibody-drug conjugates, ADC, single photon computed tomography, positron emission tomography, PET, 4-fluorobenzoic acid (FBA), 2-fluoropropionic acid (FPA), N-succinimidyl 4-fluorobenzoate, SFB, hydrazinonicotinic acid, copper-I catalyzed 1,3- dipolar cycloaddition, CuAAC, N-succinimidyl 3-iodobenzoate, SIB, 1-2 desferrioxamine, Zevalin, Epidermal Growth Factor Receptor, cetuximab, panitumumab, gefitinib, erlotinib, hEGF
Abstract: ImmunoPET is a non-invasive imaging technology based on tracking and quantification of radiolabeled monoclonal antibodies, antibody fragments and peptides in vivo. The knowledge of distribution and expression levels of a given receptor is a key for successful receptor targeted cancer therapy. ImmunoPET performed with probes with high affinity and specificity to a given receptor aspires to be a method for obtaining comprehensive information about current in vivo status of the targeted receptor. This review describes methods for radiolabeling of peptides, monoclonal antibodies, and antibody fragments for immunoPET and highlights the recently reported pre-clinical and clinical applications of immunoPET in receptor targeted therapy.
Export Options
About this article
Cite this article as:
Marik Jan and R. Junutula Jagath, Emerging Role of ImmunoPET in Receptor Targeted Cancer Therapy, Current Drug Delivery 2011; 8 (1) . https://dx.doi.org/10.2174/156720111793663589
DOI https://dx.doi.org/10.2174/156720111793663589 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advancements in Robotic and AI-Based Drug Discovery and Delivery for Neurological Disorders
Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors, pose significant challenges in drug delivery due to the blood-brain barrier's intricate structure and the complexity of neuronal networks. Traditional drug delivery methods often fall short in reaching therapeutic concentrations within the central nervous system, limiting treatment efficacy and ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access to both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Extracellular vesicles as drug delivery systems
Extracellular vesicles (EVs) are membranous vesicles released from almost all types of cells into extracellular space. EVs are categorized into different types including exosome (~30-150 nm), microvesicle or microparticle (~100-1,000 nm), apoptotic body (~1,000-5,000 nm), and others produced by different mechanisms. Since EVs bear the molecules (e.g., specific lipids, carbohydrates, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oncolytic Virotherapy for Breast Cancer Treatment
Current Gene Therapy Poxvirus Cancer Therapy
Recent Patents on Anti-Infective Drug Discovery Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy
Protein & Peptide Letters Prostaglandin E Synthase: A Novel Drug Target for Inflammation and Cancer
Current Pharmaceutical Design Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies
Current Drug Delivery The Mouse In Cancer Research Past, Present, Future
Current Genomics Telomerase Inhibitors: Potential Anticancer Agents
Mini-Reviews in Organic Chemistry Natural Products as Promising Antitumoral Agents in Breast Cancer: Mechanisms of Action and Molecular Targets.
Mini-Reviews in Medicinal Chemistry Folate Nutrigenetics: A Convergence of Dietary Folate Metabolism, Folic Acid Supplementation, and Folate Antagonist Pharmacogenetics
Drug Metabolism Letters Therapeutic Polycomb Targeting in Human Cancer
Recent Patents on Regenerative Medicine Spatial and Temporal Simulation of Human Evolution. Methods, Frameworks and Applications
Current Genomics Critical Review Upon the Role and Potential of Fluorescence and Near-Infrared Imaging and Absorption Spectroscopy in Cancer Related Cells, Serum, Saliva, Urine and Tissue Analysis
Current Medicinal Chemistry The PKB/AKT Pathway in Cancer
Current Pharmaceutical Design Thrombospondin and Apoptosis: Molecular Mechanisms and Use for Design of Complementation Treatments
Current Drug Targets Role of Human Papillomavirus in Various Cancers: Epidemiology, Screening and Prevention
Mini-Reviews in Medicinal Chemistry An Evaluation of the Antioxidant and Anticancer Properties of Complex Compounds of Copper (II), Platinum (II), Palladium (II) and Ruthenium (III) for Use in Cancer Therapy
Mini-Reviews in Medicinal Chemistry Clinical Applications of Gene Therapy in Head and Neck Cancer
Current Gene Therapy Epigenetic Regulation of Epithelial to Mesenchymal Transition
Current Cancer Drug Targets Meet Our Editorial Board Member
Mini-Reviews in Medicinal Chemistry